U.S. markets close in 3 hours 32 minutes

Iterum Therapeutics plc (ITRM)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
2.1100-0.0100 (-0.47%)
As of 12:17PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Commodity Channel Index

Commodity Channel Index

Previous Close2.1200
Bid2.0900 x 900
Ask2.1100 x 1000
Day's Range2.0000 - 2.2000
52 Week Range0.6010 - 2.5000
Avg. Volume117,860
Market Cap27.798M
Beta (5Y Monthly)2.42
PE Ratio (TTM)N/A
EPS (TTM)-2.4300
Earnings DateNov 14, 2023
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value

Subscribe to Yahoo Finance Plus to view Fair Value for ITRM

View details
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
  • Iterum Therapeutics plc
    Analyst Report: Pfizer Inc.Pfizer is one of the world's largest pharmaceutical firms, with annual sales close to $50 billion (excluding COVID-19 product sales). While it historically sold many types of healthcare products and chemicals, now prescription drugs and vaccines account for the majority of sales. Top sellers include pneumococcal vaccine Prevnar 13, cancer drug Ibrance, and cardiovascular treatment Eliquis. Pfizer sells these products globally, with international sales representing close to 50% of total sales. Within international sales, emerging markets are a major contributor.
    Fair Value
    Economic Moat
    3 days agoMorningstar
View more
  • GlobeNewswire

    Iterum Therapeutics Regains Compliance with Nasdaq Bid Price Rule

    DUBLIN, Ireland and CHICAGO, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Iterum Therapeutics plc (Nasdaq: ITRM) (the “Company”), a clinical-stage pharmaceutical company focused on developing next generation oral and IV antibiotics to treat infections caused by multi-drug resistant pathogens in both community and hospital settings, today announced that it has received a letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it has regained com

  • Insider Monkey

    Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript

    Iterum Therapeutics plc (NASDAQ:ITRM) Q3 2023 Earnings Call Transcript November 14, 2023 Operator: Hello, everyone, and welcome to the Iterum Therapeutics Third Quarter 2023 Financial Results and Business Update. My name is Harry, and I’ll be your operator today. [Operator Instructions] And I will now hand the call over to Louise Barrett, Senior Vice President, […]

  • Thomson Reuters StreetEvents

    Q3 2023 Iterum Therapeutics PLC Earnings Call

    Q3 2023 Iterum Therapeutics PLC Earnings Call